Purposing Saikosaponins for the treatment of COVID-19

Saved in:
Bibliographic Details
Published in:Medical hypotheses 2020-07, Vol.140, p.109782-109782, Article 109782
Main Authors: Bahbah, Eshak I., Negida, Ahmed, Nabet, Mohamed Salah
Format: Article
Language:English
Subjects:
Angiotensin-Converting Enzyme 2
Anti-Inflammatory Agents - pharmacology
Anti-Inflammatory Agents - therapeutic use
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Betacoronavirus - drug effects
Coronavirus Infections - complications
Coronavirus Infections - drug therapy
COVID-19
Cytokine Release Syndrome - drug therapy
Cytokine Release Syndrome - etiology
Drug Repositioning
Humans
Immunologic Factors - pharmacology
Immunologic Factors - therapeutic use
Lymphocyte Activation - drug effects
Molecular Docking Simulation
Oleanolic Acid - analogs & derivatives
Oleanolic Acid - pharmacology
Oleanolic Acid - therapeutic use
Pandemics
Peptidyl-Dipeptidase A - drug effects
Pneumonia, Viral - complications
Pneumonia, Viral - drug therapy
Receptors, Virus - drug effects
Saponins - pharmacology
Saponins - therapeutic use
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0306-9877
1532-2777
DOI:10.1016/j.mehy.2020.109782